CELLULAR INTERACTIONS IN HEMOPOIESIS

对慢性病贫血起源的研究将集中在贫血上 与癌症有关，是红细胞生成控制中的一种异常 T淋巴细胞在肿瘤发生发展中的作用。使用刘易斯肺 肿瘤诱导的T抑制细胞活性与肿瘤的关系 将评估红系细胞发育情况。使用药物西咪替丁， 免疫疗法在阻断抑制细胞活性和允许 荷瘤小鼠红系细胞的正常发育 检查过了。 正常造血生理调节因子诱导的能力 我们将研究人类白血病细胞系的分化情况。在体内， K562和HL-60细胞将被种植到扩散室内并植入 进入正常和血液学紊乱的腹膜腔 老鼠。体外研究将集中在正常人类捐赠者的能力 骨髓基质，它似乎在正常血液中发挥着重要作用 细胞发育，诱导白血病细胞分化。形态 功能成熟度将在这两项研究中进行评估。 最后，人类白血病细胞系抑制正常的能力 化学诱导剂诱导分化前后的造血 将在体外进行检测。目标将是确定是否 白血病细胞对正常造血的抑制特性在以下情况下丧失 白血病细胞经历分化。“诱导法”的功效 化疗是逆转正常人白血病细胞抑制的一种手段 因此，干细胞开发可能会提供一种替代细胞毒的方法 整复疗法，以确立缓解和治愈。(IS)

Studies on the origin of anemia in chronic disease will focus on the anemia associated with cancer as an aberration in the control of erythropoiesis by T-lymphocytes during the development of neoplasia. Using a Lewis lung carcinoma, the relationship of tumor-induced T-suppressor cell activity and erythroid cell development will be evaluated. Using the drug cimetidine, the role of immunotherapy to block suppressor cell activity and allow the normal development of erythroid cells in tumor-bearing mice will be examined. The ability of normal physiological regulators of hemopoiesis to induce differentiation in human leukemia cell lines will be examined. In vivo, K562 and HL-60 cells will be seeded into diffusion chambers and implanted into the peritoneal cavities of normal and hematologically perturbated mice. In vitro studies will focus on the abiIity of normal human donors' bone marrow stroma, which appears to play an important role in normal blood cell development, inducing leukemic cell differentiation. Morphological and functional maturation will be assessed in both studies. Finally, the ability of human leukemic cell lines to suppress normal hemopoiesis prior to and after inducing differentiation by chemical agents will be examined in vitro. The objective will be to determine whether the property of leukemic cell inhibition of normal hemopoiesis is lost when leukemic cells undergo differentiation. The efficacy of "induction chemotherapy" as a means of reversing leukemic cell suppression of normal stem cell development may thus provide an alternative to cytotoxic reduction therapy to establish remission and cure. (IS)